Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the companys total funding to date to $295M. The new capital will be used to expand Immunais drug actuary platform for target validation and evaluation.
We have made great progress towards our core mission of understanding the immune system, which we believe is essential to finding the answers to human health and disease, said Noam Solomon, PhD, CEO and co-founder of Immunai. Unlocking the immune system will accelerate the evaluation and development of novel immune medicines. Our approach is to combine best-in-class single-cell genomic methods and artificial intelligence with a deep understanding of immunology.
Immunai has leveraged its best-in-class proprietary technologies and more than 25 academic partnerships to build AMICA, the Annotated Multiomic Immune Cell Atlas, the worlds largest data atlas of clinically-annotated single-cell immune data. This atlas, combined with Immunais team of immunologists and computational biologists, provides unique insights into underlying biology that drives disease etiology, allowing the company and its partners to discover novel targets as well as analyze and develop existing pipeline compounds.
Were starting to see the payoff from building our platform and the AMICA database. The ability of our platform to surface and evaluate new drug targets has given us the confidence to push into therapeutic development with our partners. Were grateful for both the capital and expertise were receiving in the round, and will use both to develop our platform and help advance targets towards the clinic, explained Luis Voloch, CTO and co-founder of Immunai.
Immunai has tripled in size in the last year, with more than 120 employees (70 of whom are PhDs or MDs) in New York City, Tel Aviv, Zurich, Prague, and San Francisco. The company has more than 30 partnerships with Fortune 100 pharmaceutical companies and leading academic institutions, including Harvard, Stanford, Memorial Sloan Kettering, and Baylor College of Medicine.
The Series B was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and more, including previous investors.
Immunai is leaving no stone unturned in understanding and developing technology to map the immune system critical scientific work that will give us greater knowledge to treat diseases and improve patient outcomes, said Eli Groner, Managing Director at Koch Disruptive Technologies, who will be joining Immunais board of directors. We invested in Immunai because we recognize that understanding the immune system and its incredible complexity is key for the future of medicine.
The funding comes on the heels of Immunais acquisition of Nebion and the addition of world-renowned scientists and engineers, including Robert Langer, ScD, to the Board of Directors, Jacques Banchereau, PhD, as Chief Science Officer, and Mark Jacobstein as Chief Business Officer.
For more information about how to partner with Immunai or join the companys mission to reprogram the immune system, please visit Immunai.com.
Immunai uses single-cell genomics and machine learning to discover and develop novel therapeutics that reprogram the immune system. The team of 120 employees, 70 of whom are PhDs or MDs, is composed of experts in genomics, machine learning, bioinformatics, immunology, and software engineering. The company has more than 30 partnerships with Fortune 100 pharmaceutical companies and leading academic institutions, including Harvard, Stanford, Memorial Sloan Kettering, and Baylor College of Medicine. Headquartered in New York City, with offices in San Francisco, Tel Aviv, Zurich, Prague, and San Francisco, the company has raised $295M in funding to-date. For more information visit www.immunai.com.